Loading…
Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens
In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pa...
Saved in:
| Published in: | European journal of clinical microbiology & infectious diseases 2004-10, Vol.23 (10), p.772-775 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3 |
| container_end_page | 775 |
| container_issue | 10 |
| container_start_page | 772 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 23 |
| creator | HOEFFKEN, G TALAN, D LARSEN, L. S PELOQUIN, S CHOUDHRI, S. H HAVERSTOCK, D JACKSON, P CHURCH, D |
| description | In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens. |
| doi_str_mv | 10.1007/s10096-004-1214-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_612860345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2082452411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3</originalsourceid><addsrcrecordid>eNpFkE1r3DAQhkVpaTZJf0AvRRR6VKNv2ccS0jYQ6CG9i7EsNQpry5FkGp_y16NlF3IZweh5Z5gHoc-MfmeUmqvSaq8JpZIwziRR79COSaGIFEa8RzvaC0l6w8UZOi_lkbZMZ8xHdMaUpop1codebkKIDtyGYR5xgeDrhlPAxT-tfq4R9nhKzzHs0zO4OOOQMq7ZQ53a7wF0aZrWOdaNgHtaY_YjXma_TmmOgKGU5CLU1vwf6wOGui1t2x4vUB_SPz-XS_QhwL74T6f3At3_vPl7_Zvc_fl1e_3jjjihZCWio1LpDoZhMDAGzo0xXGsWzCBdR93oGYM-dJ022gTlA7jAe9qPauQQxAX6epy65NTuKtU-pjXPbaHVjHeaCqkaxI6Qy6mU7INdcpwgb5ZRe_Btj75t820Pvu0h8-U0eB0mP74lToIb8O0EQGmHhwyzi-WN05xyzYV4BTJEi24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>612860345</pqid></control><display><type>article</type><title>Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens</title><source>Springer Nature</source><creator>HOEFFKEN, G ; TALAN, D ; LARSEN, L. S ; PELOQUIN, S ; CHOUDHRI, S. H ; HAVERSTOCK, D ; JACKSON, P ; CHURCH, D</creator><creatorcontrib>HOEFFKEN, G ; TALAN, D ; LARSEN, L. S ; PELOQUIN, S ; CHOUDHRI, S. H ; HAVERSTOCK, D ; JACKSON, P ; CHURCH, D</creatorcontrib><description>In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-004-1214-5</identifier><identifier>PMID: 15605184</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Infective Agents - administration & dosage ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Aza Compounds - administration & dosage ; Aza Compounds - adverse effects ; Aza Compounds - therapeutic use ; Biological and medical sciences ; Clinical trials ; Community-Acquired Infections - drug therapy ; Female ; Fluoroquinolones ; Humans ; Infectious diseases ; Injections, Intravenous ; Male ; Medical sciences ; Middle Aged ; Pathogens ; Pharmacology. Drug treatments ; Pneumonia ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - microbiology ; Quinolines - administration & dosage ; Quinolines - adverse effects ; Quinolines - therapeutic use ; Retrospective Studies</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2004-10, Vol.23 (10), p.772-775</ispartof><rights>2004 INIST-CNRS</rights><rights>Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3</citedby><cites>FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16202623$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15605184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOEFFKEN, G</creatorcontrib><creatorcontrib>TALAN, D</creatorcontrib><creatorcontrib>LARSEN, L. S</creatorcontrib><creatorcontrib>PELOQUIN, S</creatorcontrib><creatorcontrib>CHOUDHRI, S. H</creatorcontrib><creatorcontrib>HAVERSTOCK, D</creatorcontrib><creatorcontrib>JACKSON, P</creatorcontrib><creatorcontrib>CHURCH, D</creatorcontrib><title>Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Infective Agents - administration & dosage</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Aza Compounds - administration & dosage</subject><subject>Aza Compounds - adverse effects</subject><subject>Aza Compounds - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Female</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pathogens</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - adverse effects</subject><subject>Quinolines - therapeutic use</subject><subject>Retrospective Studies</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkE1r3DAQhkVpaTZJf0AvRRR6VKNv2ccS0jYQ6CG9i7EsNQpry5FkGp_y16NlF3IZweh5Z5gHoc-MfmeUmqvSaq8JpZIwziRR79COSaGIFEa8RzvaC0l6w8UZOi_lkbZMZ8xHdMaUpop1codebkKIDtyGYR5xgeDrhlPAxT-tfq4R9nhKzzHs0zO4OOOQMq7ZQ53a7wF0aZrWOdaNgHtaY_YjXma_TmmOgKGU5CLU1vwf6wOGui1t2x4vUB_SPz-XS_QhwL74T6f3At3_vPl7_Zvc_fl1e_3jjjihZCWio1LpDoZhMDAGzo0xXGsWzCBdR93oGYM-dJ022gTlA7jAe9qPauQQxAX6epy65NTuKtU-pjXPbaHVjHeaCqkaxI6Qy6mU7INdcpwgb5ZRe_Btj75t820Pvu0h8-U0eB0mP74lToIb8O0EQGmHhwyzi-WN05xyzYV4BTJEi24</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>HOEFFKEN, G</creator><creator>TALAN, D</creator><creator>LARSEN, L. S</creator><creator>PELOQUIN, S</creator><creator>CHOUDHRI, S. H</creator><creator>HAVERSTOCK, D</creator><creator>JACKSON, P</creator><creator>CHURCH, D</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20041001</creationdate><title>Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens</title><author>HOEFFKEN, G ; TALAN, D ; LARSEN, L. S ; PELOQUIN, S ; CHOUDHRI, S. H ; HAVERSTOCK, D ; JACKSON, P ; CHURCH, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Infective Agents - administration & dosage</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Aza Compounds - administration & dosage</topic><topic>Aza Compounds - adverse effects</topic><topic>Aza Compounds - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Female</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pathogens</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - adverse effects</topic><topic>Quinolines - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOEFFKEN, G</creatorcontrib><creatorcontrib>TALAN, D</creatorcontrib><creatorcontrib>LARSEN, L. S</creatorcontrib><creatorcontrib>PELOQUIN, S</creatorcontrib><creatorcontrib>CHOUDHRI, S. H</creatorcontrib><creatorcontrib>HAVERSTOCK, D</creatorcontrib><creatorcontrib>JACKSON, P</creatorcontrib><creatorcontrib>CHURCH, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOEFFKEN, G</au><au>TALAN, D</au><au>LARSEN, L. S</au><au>PELOQUIN, S</au><au>CHOUDHRI, S. H</au><au>HAVERSTOCK, D</au><au>JACKSON, P</au><au>CHURCH, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>23</volume><issue>10</issue><spage>772</spage><epage>775</epage><pages>772-775</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>15605184</pmid><doi>10.1007/s10096-004-1214-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2004-10, Vol.23 (10), p.772-775 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_journals_612860345 |
| source | Springer Nature |
| subjects | Administration, Oral Adolescent Adult Aged Aged, 80 and over Anti-Infective Agents - administration & dosage Anti-Infective Agents - adverse effects Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Aza Compounds - administration & dosage Aza Compounds - adverse effects Aza Compounds - therapeutic use Biological and medical sciences Clinical trials Community-Acquired Infections - drug therapy Female Fluoroquinolones Humans Infectious diseases Injections, Intravenous Male Medical sciences Middle Aged Pathogens Pharmacology. Drug treatments Pneumonia Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - microbiology Quinolines - administration & dosage Quinolines - adverse effects Quinolines - therapeutic use Retrospective Studies |
| title | Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A35%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20sequential%20moxifloxacin%20for%20treatment%20of%20community-acquired%20pneumonia%20associated%20with%20atypical%20pathogens&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=HOEFFKEN,%20G&rft.date=2004-10-01&rft.volume=23&rft.issue=10&rft.spage=772&rft.epage=775&rft.pages=772-775&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-004-1214-5&rft_dat=%3Cproquest_cross%3E2082452411%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c354t-3804568abbb7adf227772661f7b4c80cde11a9f886767f5efacf2909d5d2af3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=612860345&rft_id=info:pmid/15605184&rfr_iscdi=true |